Latest acute leukemia Stories
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec.
Company Outlines Plans for Phase III Registration Study San Diego, Dec. 8, 2014 /PRNewswire/ -- MEI Pharma, Inc.
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.
SAN FRANCISCO, Dec.
TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy. San Diego, California (PRWEB) December
--CHOP-Led Pilot Study Engineers Patients' Own Immune Cells to Hunt Down Cancer Cells in Blood-- PHILADELPHIA, Dec.
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.
SAN DIEGO AND TORONTO, Dec.
Interim Data from 33 Evaluable Patients to be Presented at ASH on Saturday SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc.
WHITE PLAINS, N.Y., Dec.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.